FRAX and the effect of teriparatide on vertebral and non-vertebral fracture

What Was Tested

The paper reports a study of Teriparatide, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Teriparatide study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Teriparatide, giving a reference point.

Baseline clinical risk factors were entered into country-specific FRAX models to compute the 10-year probability of major osteoporotic fractures with or without input of femoral neck BMD.

What Was Measured

Topics PubMed links to this paper include Bone Density, Bone Density Conservation Agents, Hip Fractures, Osteoporosis, Postmenopausal, Osteoporotic Fractures, Risk Assessment and Risk Factors.

Author keywords: BMD, Epidemiology, FRAX, Interaction, Randomised controlled trial and Teriparatide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teriparatide.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, all human trials.